Brit Mollenhauer

Summary

Affiliation: Paracelsus Hospital
Country: Germany

Publications

  1. doi request reprint [Early recognition of Parkinson's disease : Objectifiable non-motor symptoms and biomarkers]
    B Mollenhauer
    Paracelsus Elena Klinik, Klinikstr 16, 34119, Kassel, Deutschland
    Nervenarzt 84:918-26. 2013
  2. doi request reprint Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Neurosci Lett 532:44-8. 2013
  3. pmc α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
    Brit Mollenhauer
    Paracelsus Elena Klinik, Klinikstrasse 16, 34128, Kassel, Germany
    J Neural Transm 119:739-46. 2012
  4. doi request reprint α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Lancet Neurol 10:230-40. 2011
  5. doi request reprint CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease
    Brit Mollenhauer
    Paracelsus Elena Klinik Kassel and Department of Neurology, Georg August University, Gottingen, Germany
    J Alzheimers Dis 24:383-91. 2011
  6. doi request reprint Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel and Georg August University, Gottingen, Germany
    J Neural Transm 118:691-7. 2011
  7. pmc Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Dtsch Arztebl Int 107:684-91. 2010
  8. doi request reprint Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Klinikstrasse 16, 34128 Kassel, Germany
    Biomark Med 4:683-99. 2010
  9. doi request reprint Neurochemical biomarkers in the differential diagnosis of movement disorders
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 24:1411-26. 2009
  10. ncbi request reprint Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:376-82. 2005

Detail Information

Publications24

  1. doi request reprint [Early recognition of Parkinson's disease : Objectifiable non-motor symptoms and biomarkers]
    B Mollenhauer
    Paracelsus Elena Klinik, Klinikstr 16, 34119, Kassel, Deutschland
    Nervenarzt 84:918-26. 2013
    ..This article reviews important NMSs (e.g. RBD, hyposmia and neuropsychiatric/cognitive symptoms) as well as the current status on biomarkers and brain imaging in early (premotor) phases of PD and their relevance for the early diagnosis. ..
  2. doi request reprint Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Neurosci Lett 532:44-8. 2013
    ..Follow-up investigations will determine the usefulness of CSF α-synuclein values as markers of progression in individual subjects...
  3. pmc α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
    Brit Mollenhauer
    Paracelsus Elena Klinik, Klinikstrasse 16, 34128, Kassel, Germany
    J Neural Transm 119:739-46. 2012
    ..We conclude from these complementary results that despite its higher levels in peripheral blood products, neurons of the brain and spinal cord represent the principal source of aSyn in human CSF...
  4. doi request reprint α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Lancet Neurol 10:230-40. 2011
    ..We aimed to assess whether reduction of α-synuclein concentrations in CSF was a marker for α-synuclein deposition in the brain, and therefore diagnostic of synucleinopathies...
  5. doi request reprint CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease
    Brit Mollenhauer
    Paracelsus Elena Klinik Kassel and Department of Neurology, Georg August University, Gottingen, Germany
    J Alzheimers Dis 24:383-91. 2011
    ..Our results underline the usefulness of the CSF Aβ(1-42%) and Aβ(1-40ox%) as diagnostic biomarkers for AD and DLB, respectively...
  6. doi request reprint Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel and Georg August University, Gottingen, Germany
    J Neural Transm 118:691-7. 2011
    ..There was no difference in the soluble fractions of brain homogenate in AD and CJD. We therefore conclude that different mechanisms in AD and CJD are responsible for the Aβ1-42 decrease in the CSF...
  7. pmc Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Dtsch Arztebl Int 107:684-91. 2010
    ..Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are the two most common types of dementing neurodegenerative disease after Alzheimer's disease (AD). Both of these conditions are often diagnosed late or not at all...
  8. doi request reprint Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Klinikstrasse 16, 34128 Kassel, Germany
    Biomark Med 4:683-99. 2010
    ..We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts...
  9. doi request reprint Neurochemical biomarkers in the differential diagnosis of movement disorders
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 24:1411-26. 2009
    ..In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF alpha-synuclein findings)...
  10. ncbi request reprint Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:376-82. 2005
    ..However, there is a special interest in finding biochemical markers to monitor disease progression for differential diagnosis and treatment...
  11. ncbi request reprint Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
    ..From the presented results, we consider the ratio of plasma Abeta1-38/Abeta1-40 peptides to be a blood-based biomarker candidate for VAD...
  12. ncbi request reprint CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Mirko Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Brain 129:1177-87. 2006
    ..Their distinct molecular phenotypes support the view of different pathophysiological pathways for each of these neurodegenerative diseases...
  13. doi request reprint Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease
    Peter Brechlin
    Department of Neurodegeneration and Restorative Research, Center of Neurological Medicine, University of Goettingen, Goettingen, Germany
    Proteomics 8:4357-66. 2008
    ..We conclude that our proteomic approach is useful to differentiate CJD from other neurodegenerative diseases and expect that CSF-optimized 2-D DIGE will find broad application in the search for other brain derived proteins in CSF...
  14. ncbi request reprint Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia
    Brit Mollenhauer
    Department of Neurology, Georg August University, Kassel, Germany
    Dement Geriatr Cogn Disord 22:200-8. 2006
    ..These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD...
  15. ncbi request reprint Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Department of Neurology, Georg August University Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:164-70. 2005
    ..We conclude that more specific markers have to be established for the differentiation of these diseases...
  16. doi request reprint Associated factors for REM sleep behavior disorder in Parkinson disease
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Neurology 77:1048-54. 2011
    ..To investigate the frequency, phenomenology, and associated risk factors of REM sleep behavior disorder (RBD) in Parkinson disease (PD)...
  17. pmc Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    J Clin Sleep Med 7:75-80. 2011
    ..To develop a polysomnographic video-based scale for rating the severity of REM sleep behavior disorder (RBD), to classify the severity of RBD and to determine the intraindividual variability of RBD in patients with Parkinson disease (PD)...
  18. doi request reprint Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease?
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Kassel, Germany
    Sleep Med 13:1178-83. 2012
    ..To describe the alterations in the macrostructure of sleep in a large cohort of sleep-disturbed patients with Parkinson's disease (PD) and investigate influencing factors...
  19. doi request reprint Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of experimental neurodegenerative diseases
    Sandra Ebert
    Department of Neurology, University of Gottingen, Gottingen, Germany
    J Neurosci Res 88:1124-36. 2010
    ..pneumoniae, indicating that the effect of moderately severe acute infections on the course of neurodegenerative diseases may be less pronounced than suspected...
  20. doi request reprint Movement disturbances in the differential diagnosis of Creutzfeldt-Jakob disease
    Jan Edler
    Department of Neuropathology, University Medical Center, Gottingen, Germany
    Mov Disord 24:350-6. 2009
    ..Our results indicate that the careful assessment of movement disturbances may be helpful in the differential diagnosis of Creutzfeldt-Jakob disease...
  21. pmc Biochemical premotor biomarkers for Parkinson's disease
    Brit Mollenhauer
    Paracelsus Elena Klinik and Georg August University Goettingen, Kassel, Germany
    Mov Disord 27:644-50. 2012
    ....
  22. doi request reprint Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy
    Friederike Sixel-Döring
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Sleep Med 10:407-15. 2009
    ....
  23. doi request reprint The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases
    Friederike Sixel-Döring
    Center of Parkinsonism and Movement Disorders, Paracelsus Elena Klinik, Klinikstr 16, 34128, Kassel, Germany
    J Neurol 258:2147-54. 2011
    ..There was no evidence of a decrease in DAT binding in the majority of patients with postural and/or kinetic tremor. The striatal asymmetry index is a further helpful tool for differentiating PD from non-PD tremor syndromes...
  24. ncbi request reprint Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease
    Andreas Meier
    Department of Psychiatry and Psychotherapy, Sleep Disorders Center, Georg August University, Von Siebold Strasse 5, 37075 Goettingen, Germany
    Brain Res 1063:201-3. 2005
    ..All patients of the HD group and eleven patients of the non-HD group showed normal hypocretin-1 levels. Thus, hypocretin-1 may not serve as an additional diagnostic marker for HD...